đź“Š Evidence-Based Reference
optilume urethral drug coated balloon
Urotronic
Summary: The Optilume urethral drug-coated balloon is a device used for treating urethral stricture disease. It combines mechanical dilation with localized drug delivery to reduce recurrence rates. Key evidence suggests it may be more effective than conventional treatments.
FDA Clearance Information
Pathway PMA
Number P210020 ↗
Decision Date May 17, 2022
Product Code QRH
Device Class Class 3
Evidence 0 studies
The Optilume urethral drug-coated balloon by Urotronic was cleared through the PMA pathway on May 17, 2022. It is classified as a Class 3 medical device.
What It Is
The Optilume urethral drug-coated balloon is designed to treat urethral strictures by mechanically dilating the urethra while delivering paclitaxel, an antiproliferative drug, to prevent scar tissue formation. It is intended for use in patients with recurrent urethral strictures.
Clinical Applications
Commonly used in cases of recurrent anterior urethral strictures, the Optilume balloon provides an alternative to more invasive procedures like urethroplasty. It is particularly useful for strictures that are small and located in the anterior urethra.
Evidence Summary
The literature includes 15 studies, comprising systematic reviews, meta-analyses, and randomized controlled trials, involving approximately 457 patients. The studies span from recent years up to 2025.
Reported Outcomes
Published studies report that the Optilume drug-coated balloon is effective in reducing the recurrence of urethral strictures. It has been shown to improve quality of life and may lower the need for re-treatment compared to standard endoscopic management. The ROBUST III trial demonstrated its efficacy over a 2-year follow-up period.
Safety Profile
Reported complications include typical post-procedural discomfort and transient urinary symptoms. No significant adverse events were highlighted in the studies, indicating a favorable safety profile.
Evidence Limitations
Current evidence is limited by the relatively short follow-up periods and the need for more diverse patient populations. Further research is needed to confirm long-term efficacy and safety across different clinical settings.
Frequently Asked Questions
What are the clinical indications for Optilume urethral drug-coated balloon?
The Optilume balloon is indicated for the treatment of recurrent anterior urethral strictures, particularly those that are small and located in the anterior urethra.
What outcomes have been reported in clinical studies?
Studies report reduced recurrence rates of urethral strictures and improved quality of life. The device may lower the need for re-treatment compared to conventional methods.
What complications have been reported?
Reported complications include transient urinary symptoms and post-procedural discomfort, with no significant adverse events noted in the studies.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.